![Philip Nickson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Philip Nickson
Conseiller Juridique Général chez
MONTE ROSA THERAPEUTICS, INC.
Fortune : 1 M $ au 31/05/2026
Profil
Philip Nickson is currently Chief Business & Legal Officer at Monte Rosa Therapeutics, Inc. since 2024.
Previously, Dr. Nickson was Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Education includes a doctorate from The University of Manchester and a graduate degree from Suffolk University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/04/2026 | 55 000 ( 0,07 % ) | 1 M $ | 31/05/2026 |
Postes actifs de Philip Nickson
| Sociétés | Poste | Début |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Conseiller Juridique Général | 01/03/2021 |
Anciens postes connus de Philip Nickson
| Sociétés | Poste | Fin |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/03/2021 |
Formation de Philip Nickson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
26
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that discovers and develops novel biologic therapies for the treatment of rare immune-mediated diseases | Health Technology |
The University of Manchester
 The University of Manchester Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Suffolk University
 Suffolk University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Monte Rosa Therapeutics, Inc.
 Monte Rosa Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecular glue degrader medicines for oncology, autoimmune and inflammatory diseases | Health Technology |
